ライフサイエンスコーパス: impaired fasting glucose

1 terol, high triglycerides, hypertension, and impaired fasting glucose).

2 xperience the onset of diabetes mellitus and impaired fasting glucose.

3 ciated with higher incidence of diabetes and impaired fasting glucose.

4 also associated with increased prevalence of impaired fasting glucose.

5 One subject taking placebo developed impaired fasting glucose.

6 own hypertension, dyslipidemia, diabetes, or impaired fasting glucose.

7 d type 2 diabetes and 593 patients developed impaired fasting glucose.

8 HgbA1C and was elevated in obese humans with impaired fasting glucose.

9 her incidence of MACCE were hypertension and impaired fasting glucose.

10 ral population initially free of diabetes or impaired fasting glucose.

11 preventing T2DM in individuals with isolated impaired fasting glucose.

12 th type 2 diabetes and 266 participants with impaired fasting glucose.

13 interventions for individuals with isolated impaired fasting glucose.

14 ipoprotein cholesterol levels, and 15.3% had impaired fasting glucose.

15 among nondiabetic, postmenopausal women with impaired fasting glucose.

16 s and weaker among those without diabetes or impaired fasting glucose.

17 e symptoms were 0.79 (95% CI, 0.63-0.99) for impaired fasting glucose, 0.75 (95% CI, 0.44-1.27) for u

18 rction had a higher annual incidence rate of impaired fasting glucose (1.8 vs 27.5% in our study) and

19 zed as normal fasting glucose (< 100 mg/dL), impaired fasting glucose (100-125 mg/dL), or type 2 diab

20 Impaired fasting glucose (100-125 vs. <90 mg/dL), elevat

21 having normal fasting glucose (<110 mg/dL), impaired fasting glucose (110 to <126 mg/dL), or undiagn

22 sterol (25.6%, 23.1-28.26%), and diabetes or impaired fasting glucose (25.0%, 22.6-27.5%).

23 ipants with normal fasting glucose; 27.9 for impaired fasting glucose; 31.2 for untreated type 2 diab

24 line), undiagnosed hyperglycemia (4.9%), and impaired fasting glucose (36.5% in those not known to be

25 te recovery was more common among those with impaired fasting glucose (42 vs. 31%; relative risk, 1.3

26 layers had significantly lower prevalence of impaired fasting glucose (6.7% [n = 24]; 95% CI, 4.6%-8.

27 Women with impaired fasting glucose according to either definition

28 The 218 women with impaired fasting glucose according to the 1997 definitio

29 CI, 1.08 to 1.74]), while the 698 women with impaired fasting glucose according to the 2003 definitio

30 196 (15%) had impaired glucose tolerance or impaired fasting glucose and 171 entered the trial.

31 re 27 diabetics and 50 prediabetics (17 with impaired fasting glucose and 33 with impaired glucose to

32 1.9-fold risk (95% CI, 1.5- to 2.4-fold) for impaired fasting glucose and a 3.7-fold risk (CI, 2.4- t

33 normal baseline fasting glucose, those with impaired fasting glucose and diabetes had adjusted relat

34 should be tested to evaluate the patient for impaired fasting glucose and diabetes mellitus.

35 e progression from normal fasting glucose to impaired fasting glucose and diabetes.

36 Impaired fasting glucose and hypertension were associate

37 impaired glucose tolerance (Ob-NFG-IGT), (c) impaired fasting glucose and IGT (Ob-IFG-IGT), or (d) ty

38 Impaired fasting glucose and IGT are associated with mod

39 wo major phenotypes of prediabetes, that is, impaired fasting glucose and impaired glucose tolerance,

40 al relationship between elevated lactate and impaired fasting glucose and insulin resistance.

41 ed associations between miRNAs and prevalent impaired fasting glucose and T2D and evaluated the T2D-a

42 gs suggest a dose-response relationship with impaired fasting glucose and T2D.

43 rventions are beneficial in individuals with impaired fasting glucose and those of normal body weight

44 10-139 mg/dL]) should be diagnosed as having impaired fasting glucose and treated with an appropriate

45 nd personal characteristics and incidence of impaired fasting glucose and type 2 diabetes.

46 tness was associated with increased risk for impaired fasting glucose and type 2 diabetes.

47 ted with the onset of objectively determined impaired fasting glucose and type 2 diabetes.

48 Impaired fasting glucose and untreated type 2 diabetes w

49 IGR was defined as impaired fasting glucose and/or impaired glucose toleran

50 idence of hyperglycemia (type 2 diabetes and impaired fasting glucose) and insulin regulation in a 9-

51 ia as a marker for diabetes and prediabetes (impaired fasting glucose) and insulin resistance in youn

52 A total of 504 participants (10%) had impaired fasting glucose, and 131 (3%) had untreated dia

53 eline, 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglyce

54 Incidences of diabetes, impaired fasting glucose, and cardiovascular events were

55 population and is associated with older age, impaired fasting glucose, and cirrhosis.

56 low HDL cholesterol, elevated triglycerides, impaired fasting glucose, and Dietary Guidelines for Ame

57 individuals, the prevalence of hypertension, impaired fasting glucose, and metabolic syndrome increas

58 latter included impaired glucose tolerance, impaired fasting glucose, and newly diagnosed diabetes).

59 betic patients and nondiabetic patients with impaired fasting glucose are at high risk of recurrent c

60 association was present in participants with impaired fasting glucose at baseline (aHR: 0.61; 95% CI:

61 udy who were aged 42-60 y and free of T2D or impaired fasting glucose at baseline in 1984-1989.

62 Of the 7533 without impaired fasting glucose at baseline, 2514 (33%) develop

63 who were not diagnosed as diabetic, 342 had impaired fasting glucose at entry defined by the America

64 dence interval 1.35, 2.48) increased odds of impaired fasting glucose at follow-up.

65 for developing diabetes: metabolic syndrome, impaired fasting glucose, body-mass index 30 kg/m(2) or

66 rease in the proportion of participants with impaired fasting glucose but not a clinical diagnosis of

67 concentration <6.1 mmol/L [110 mg/dL]); (2) impaired fasting glucose by the new criterion (FPG conce

68 intolerance (impaired glucose tolerance and impaired fasting glucose combined, 15.2%; previously und

69 omen, and with impaired glucose tolerance or impaired fasting glucose determined by oral glucose tole

70 rol and with increased odds of hypertension, impaired fasting glucose, diabetes mellitus, and metabol

71 Projections to 2020 suggest that obesity and impaired fasting glucose/diabetes mellitus could increas

72 ns such as metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, ob

73 hout diagnosed diabetes; n = 55 (2.9%)), and impaired fasting glucose (fasting blood glucose 5.6-6.9

74 ation or fasting glucose > or =7 mmol/L) and impaired fasting glucose (fasting glucose > or =6.1 mmol

75 as no association between R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or

76 abnormal metabolic features characterized by impaired fasting glucose, glucose intolerance, hyperinsu

77 ubjects with diabetes mellitus or those with impaired fasting glucose/glucose tolerance is therefore

78 These nondiabetic patients with impaired fasting glucose had a higher rate of recurrent

79 Clinically, a similar profile of impaired fasting glucose has been associated with hepati

80 ard ratio per decade, 2.2; 95% CI, 1.7-2.7), impaired fasting glucose (hazard ratio, 2.6; 95% CI, 1.3

81 Among individuals with impaired fasting glucose, HbA1c concentrations were norm

82 current alcohol use, hypertension, diabetes/impaired fasting glucose, homeostatic model assessment o

83 1985 World Health Organization criteria) and impaired fasting glucose (IFG) (as defined by the 1997 A

84 pathway, was associated with development of impaired fasting glucose (IFG) after atenolol treatment.

85 Thirty-two subjects with impaired fasting glucose (IFG) and 28 subjects with norm

86 Many kidney donor candidates with impaired fasting glucose (IFG) and all candidates with d

87 fects in beta-cell function in subjects with impaired fasting glucose (IFG) and compare the results t

88 ed without an oral glucose tolerance test as impaired fasting glucose (IFG) and high HbA(1c) are also

89 NFG and impaired glucose tolerance (IGT), 3) impaired fasting glucose (IFG) and IGT, and 4) type 2 di

90 Impaired fasting glucose (IFG) and impaired glucose tole

91 Impaired fasting glucose (IFG) and impaired glucose tole

92 diate stage of prediabetes, characterized by impaired fasting glucose (IFG) and impaired glucose tole

93 ) for cardiovascular disease associated with impaired fasting glucose (IFG) and impaired glucose tole

94 her there is a fecal metabolite signature of impaired fasting glucose (IFG) and the possible underlyi

95 ew studies assessing pre-hypertension and an impaired fasting glucose (IFG) and their combined effect

96 dolescent weight gain and the development of impaired fasting glucose (IFG) and type 2 diabetes (T2DM

97 and clinical outcomes, in all patients with impaired fasting glucose (IFG) and type T2DM undergoing

98 ecretion and insulin action in subjects with impaired fasting glucose (IFG) and/or impaired glucose t

99 ied diabetes was found in 19% (n = 100), and impaired fasting glucose (IFG) and/or impaired glucose t

100 of gut microbiome function, associated with impaired fasting glucose (IFG) in 142 individuals with I

101 determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV-infected m

102 asis and their association with diabetes and impaired fasting glucose (IFG) in Fukuoka, Japanese subj

103 Impaired fasting glucose (IFG) is more prevalent in men

104 ed hemoglobin (HbA1c) level of 5.7% to 6.4%, impaired fasting glucose (IFG) level (FG level of 100-12

105 jectory: stable normoglycemia; 5 patterns of impaired fasting glucose (IFG) not progressing to diabet

106 American Diabetes Association definition of impaired fasting glucose (IFG) on prevalence of IFG, cor

107 Pre-diabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose toler

108 We sought to determine whether impaired fasting glucose (IFG) predicts cardiovascular d

109 A diagnosis of NODAT, IGT, and impaired fasting glucose (IFG) was based on World Health

110 he number of composite traits: hypertension, impaired fasting glucose (IFG), high fasting insulin, lo

111 ssion from normal glucose tolerance (NGT) to impaired fasting glucose (IFG), impaired glucose toleran

112 This study assessed whether impaired fasting glucose (IFG), insulin resistance, and

113 tion and treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tole

114 tion and beta-cell function in subjects with impaired fasting glucose (IFG).

115 ulin secretion and action and is preceded by impaired fasting glucose (IFG).

116 ey donors from 1994 to 2007 with predonation impaired fasting glucose (IFG).

117 udy was to assess the cardiovascular risk of impaired fasting glucose (IFG).

118 ic insulin resistance to the pathogenesis of impaired fasting glucose (IFG).

119 ation (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting glucose (IFG, FPG 110-125 mg/dl), and t

120 /dL (SD = 10.7), 18% of the participants had impaired fasting glucose (IFG; i.e., 100-125 mg/dL FBG)

121 vision incorporating the lower threshold for impaired fasting glucose [IFG]) and early-onset coronary

122 ic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjec

123 27 kg/m(2); 41 with type 2 diabetes, 15 with impaired fasting glucose [IFG], and 35 nondiabetic subje

124 pants as having isolated prediabetes defect (impaired fasting glucose [IFG], impaired glucose toleran

125 6 mmol/L and no self-reported history of DM; impaired fasting glucose [IFG]: FPG 5.6-6.9 mmol/L and n

126 eria, a new category was introduced, termed "impaired fasting glucose" (IFG).

127 curacies of 4 screening tests in identifying impaired fasting glucose, impaired glucose tolerance (IG

128 model for the pathogenesis and treatment of impaired fasting glucose, impaired glucose tolerance, an

129 ry with the risk of developing dysglycaemia [impaired fasting glucose, impaired glucose tolerance, an

130 SPSTF reviewed the evidence on screening for impaired fasting glucose, impaired glucose tolerance, an

131 AGM was defined as impaired fasting glucose, impaired glucose tolerance, an

132 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or

133 high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or

134 g in 39 overweight or obese individuals with impaired fasting glucose, impaired glucose tolerance, or

135 ends of LE8 scores among preDM participants (impaired fasting glucose, impaired oral glucose toleranc

136 thirds of patients (n = 28) met criteria for impaired fasting glucose/impaired glucose tolerance or d

137 in patients with type 2 diabetes mellitus or impaired fasting glucose/impaired glucose tolerance that

138 at in patients with type 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a s

139 glucose tolerance: normal glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or

140 l studies established a higher prevalence of impaired fasting glucose in men and impaired glucose tol

141 isk factors for, development of diabetes and impaired fasting glucose in patients who have had a myoc

142 ndent risk factors for new-onset diabetes or impaired fasting glucose included older age, hypertensio

143 larger NFL players had a lower prevalence of impaired fasting glucose, less reported smoking, a simil

144 13.2%), dyslipidemia in 55 patients (25.1%), impaired fasting glucose level in 7 patients (3.2%), and

145 density lipoprotein (HDL) cholesterol level, impaired fasting glucose level, type 2 diabetes mellitus

146 idemia (50%), elevated blood pressure (49%), impaired fasting glucose levels (26%), and diabetes mell

147 2.72]; P = .01) but were less likely to have impaired fasting glucose levels (adjusted relative risk

148 = 18) and individuals with obesity (OB) with impaired fasting glucose levels (OB+IFG) and without (n

149 In individuals with obesity and impaired fasting glucose levels (OB+IFG), following a di

150 erval (C.I.) 1.39-3.92; P = 0.0015] and have impaired fasting glucose levels (odds ratio 3.53; 95% C.

151 risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was

152 Persons with impaired fasting glucose levels may also have increased

153 Of 23 patients with impaired fasting glucose levels of 111-126 mg/dl, 14 (61

154 high-sensitivity C-reactive protein levels, impaired fasting glucose levels, dyslipidemia, elevated

155 The risk of impaired fasting glucose levels, elevated blood pressure

156 In addition to diabetes and impaired fasting glucose levels, low fasting plasma gluc

157 ined associated with diabetes, hypertension, impaired fasting glucose, metabolic syndrome, HDL, trigl

158 glucose tolerance test to determine whether impaired fasting glucose observed in FSD MORF1 males was

159 in TG/HDL-C of 1.35 (CI, 1.26-1.45), and for impaired fasting glucose of 1.31 (CI, 1.05-1.64).

160 3859 (62%) of 6229 with the lower cutoff for impaired fasting glucose of 5.6 mmol/L (incidence 321 ca

161 at baseline, 2514 (33%) developed new-onset impaired fasting glucose or diabetes (incidence 123 case

162 More effective treatments are needed for impaired fasting glucose or glucose intolerance, known a

163 on or elevated blood pressure, dyslipidemia, impaired fasting glucose or glucose tolerance, or mixed

164 normal glucose tolerance to prediabetes (ie, impaired fasting glucose or impaired glucose tolerance)

165 fulfilled the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance)

166 S. adults have diabetes and another 37% have impaired fasting glucose or impaired glucose tolerance.

167 l glucose tolerance, and 21 participants had impaired fasting glucose or impaired glucose tolerance.

168 with normal glucose tolerance and those with impaired fasting glucose or impaired glucose tolerance.

169 This was not observed in patients with impaired fasting glucose or impaired glucose tolerance.

170 ), hypertension (OR 2.73, 95% CI 2.16-3.44), impaired fasting glucose (OR 2.95, 95% CI 2.32-3.75), in

171 betes on the basis of either the presence of impaired fasting glucose (or prediabetes in countries wi

172 cumference (OR, 1.30; 95% CI, 1.09 to 1.56), impaired fasting glucose (OR, 1.25; 95% CI, 1.05 to 1.48

173 6.76; for BMI >/=27.5 kg/m(2) ), diabetes or impaired fasting glucose (OR, 4.45; CI, 1.10-30.0), and

174 red glucose tolerance) and/or fasting state (impaired fasting glucose) or by intermediate HbA(1c) lev

175 ary to diabetes, impaired glucose tolerance, impaired fasting glucose, or stress-induced is common in

176 VD risk factors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome).

177 (P<0.0001), hypertension (P<0.0001 to 0.01), impaired fasting glucose (P<0.0001 to 0.001), diabetes m

178 was influenced by the presence or absence of impaired fasting glucose (P=0.002 for the interaction) b

179 predictive of cardiovascular morbidity than impaired fasting glucose, probably because it is a bette

180 ance and insulin sensitivity as well as with impaired fasting glucose production in Atp7b (-/-) mice.

181 re affected and how undiagnosed diabetes and impaired fasting glucose relate to cognitive performance

182 y lipoprotein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to

183 about fasting blood glucose concentration or impaired fasting glucose status did not significantly im

184 Among participants with impaired fasting glucose, there were -8.3% (95% confiden

185 drug-naive patients with schizophrenia have impaired fasting glucose tolerance and are more insulin

186 This study examined the prevalence of impaired fasting glucose tolerance in first-episode, dru

187 irst-episode patients with schizophrenia had impaired fasting glucose tolerance, compared to none of

188 Impaired fasting glucose was associated with incident CV

189 Impaired fasting glucose was associated with increased i

190 The risk for impaired fasting glucose was elevated in older men and t

191 opathy (OR 3.01, 95% CI 1.60 to 5.65), while impaired fasting glucose was not (OR 1.55, 95% CI 0.70 t

192 nary artery disease, the 2003 definition for impaired fasting glucose was not associated with increas

193 nfidence interval [CI] = 1.29-2.83); whereas impaired fasting glucose was unassociated.

194 risk-factors with incidence of diabetes and impaired fasting glucose were assessed with multivariabl

195 ients, however, hypertension and diabetes or impaired fasting glucose were significant only among non

196 etes and prediabetes (insulin resistance and impaired fasting glucose) were higher among persons with

197 3 nondiabetic men (of whom 7511 did not have impaired fasting glucose) who were examined at least twi